Reirradiation of recurrent cervical cancer

doi:10.3760/cma.j.issn.1673-422X.2015.02.020

Abstract

Abstract: Pelvic exenteration, first line salvage therapy for selected recurrent cervical cancer patients, is accompanied by a high operative mortality and loss of structure and function of pelvic organs. Advances in radiation therapy, especially 3dimensional brachytherapy and stereotactic body radiotherapy, provide the opportunity to achieve similar efficacy of pelvic exenteration with acceptable complications and protect the structure and function of pelvic organs.

Key words: Uterine cervical neoplasms, Brachytherapy, Radiosurgery, Reirradiation

Zhang Xiang, Yu Hua. Reirradiation of recurrent cervical cancer[J]. Journal of International Oncology, 2015, 42(2): 153-156.

References

［1］ Zanagnolo V, Minig LA, Gadducci A, et al. Surveillance procedures for patients for cervical carcinoma: a review of the literature［J］. Int J Gynecol Cancer, 2009, 19(3): 306-313. ［2］ Dimopoulos JC, Lang S, Kirisits C, et al. Dosevolume histogram parameters and local tumor control in magnetic resonance imageguided cervical cancer brachytherapy［J］. Int J Radiat Oncol Biol Phys, 2009, 75(1): 56-63. ［3］ Peiretti M, Zapardiel I, Zanagnolo V, et al. Management of recurrent cervical cancer: a review of the literature［J］. Surg Oncol, 2012, 21(2): e59-66. ［4］ Potter R, HaieMeder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (Ⅱ): concepts and terms in 3D imagebased treatment planning in cervix cancer brachytherapy3D dose volume parameters and aspects of 3D imagebased anatomy, radiation physics, radiobiology［J］. Radiother Oncol, 2006, 78(1): 67-77. ［5］ HaieMeder C, Potter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GECESTRO Working Group (Ⅰ): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV［J］. Radiother Oncol, 2005, 74(3): 235-245. ［6］ Hellebust TP, Kirisits C, Berger D, et al. Recommendations from Gynaecological (GYN) GECESTRO Working Group: considerations and pitfalls in commissioning and applicator reconstruction in 3D imagebased treatment planning of cervix cancer brachytherapy［J］. Radiother Oncol, 2010, 96(2): 153-160. ［7］ Murakami N, Kasamatsu T, Sumi M, et al. Vaginal tolerance of CT based imageguided highdose rate interstitial brachytherapy for gynecological malignancies［J］. Radiat Oncol, 2014, 9(1): 31. ［8］ Yoshida K, Yamazaki H, Nakamura S, et al. Reirradiation using interstitial brachytherapy increases vaginal mucosal reaction compared to initial brachytherapy in patients with gynecological cancer［J］. Anticancer Res, 2013, 33(12): 5687-5692. ［9］ ZolciakSiwinska A, Bijok M, JonskaGmyrek J, et al. HDR brachytherapy for the reirradiation of cervical and vaginal cancer: Analysis of efficacy and dosage delivered to organs at risk［J］. Gynecol Oncol, 2014, 132(1): 93-97. ［10］ Abusaris H, Hoogeman M, Nuyttens JJ. Reirradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region［J］. Technol Cancer Res Treat, 2012, 11(6): 591-597. ［11］ Mabuchi S, Takahashi R, Isohashi F, et al. Reirradiation using highdoserate interstitial brachytherapy for locally recurrent cervical cancer: a single institutional experience［J］. Int J Gynecol Cancer, 2014, 24(1): 141-148. ［12］ MartinezMonge R, Cambeiro M, RodriguezRuiz ME, et al. Phase Ⅱ trial of imagebased highdoserate interstitial brachytherapy for previously irradiated gynecologic cancer［J］. Brachytherapy, 2014, 13(3): 219-224. ［13］ Badakh DK, Grover AH. Reirradiation with highdoserate remote afterloading brachytherapy implant in patients with locally recurrent or residual cervical carcinoma［J］. J Cancer Res Ther, 2009, 5(1): 24-30. ［14］ Xiang EW, Shumo C, Yaqin D, et al. Treatment of late recurrent vaginal malignancy after initial radiotherapy for carcinoma of the cervix: an analysis of 73 cases［J］. Gynecol Oncol, 1998, 69(2): 125-129. ［15］ Mahantshetty U, Kalyani N, Engineer R, et al. Reirradiation using highdoserate brachytherapy in recurrent carcinoma of uterine cervix［J］. Brachytherapy, 2014, In press. ［16］ Brabham JG, Cardenes HR. Permanent interstitial reirradiation with 198Au as salvage therapy for low volume recurrent gynecologic malignancies: a single institution experience［J］. Am J Clin Oncol, 2009, 32(4): 417-422. ［17］ Nguyen PL, Devlin PM, Beard CJ, et al. Highdoserate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature［J］. Brachytherapy, 2013, 12(1): 77-83. ［18］ Kishi K, Sonomura T, Shirai S, et al. Critical organ preservation in reirradiation brachytherapy by injectable spacer［J］. Int J Radiat Oncol Biol Phys, 2009, 75(2): 587-594. ［19］ Viswanathan AN, Damato AL, Nguyen PL. Novel use of a hydrogel spacer permits reirradiation in otherwise incurable recurrent gynecologic cancers［J］. J Clin Oncol, 2013, 31(34): e446-447. ［20］ Dewas S, Bibault JE, Mirabel X, et al. Robotic imageguided reirradiation of lateral pelvic recurrences: preliminary results［J］. Radiat Oncol, 2011, 6: 77. ［21］ Guckenberger M, Bachmann J, Wulf J, et al. Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer［J］. Radiother Oncol, 2010, 94(1): 53-59. ［22］ Deodato F, Macchia G, Grimaldi L, et al. Stereotactic radiotherapy in recurrent gynecological cancer: a case series［J］. Oncol Rep, 2009, 22(2): 415-419.

[1]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[2]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[3]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[4]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.
[5]	Ma Xueyan, Lu Lili, Sun Pengfei. Advances in the immune microenvironment in cervical cancer [J]. Journal of International Oncology, 2023, 50(1): 47-50.
[6]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[7]	Shi Yingxia, Hu Lijun, Yu Jingping. Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 568-571.
[8]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.
[9]	Yuan Chenyang, Zhou Juying. Research progress on prognostic factors of cervical cancer [J]. Journal of International Oncology, 2022, 49(5): 307-313.
[10]	Yang Wenbo, Xiao Li, Bi Jianqiang, Sun Yunchuan. Application of ¹⁹²Ir brachytherapy combined with external beam radiation and biliary stent in the treatment of unresectable hilar cholangiocarcinoma [J]. Journal of International Oncology, 2022, 49(2): 95-99.
[11]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting. Screening and treatment progression of elderly cervical cancer [J]. Journal of International Oncology, 2022, 49(12): 754-758.
[12]	Du Xiao, Zhou Juying. Stereotactic body radiotherapy for localized prostate cancer [J]. Journal of International Oncology, 2021, 48(5): 313-316.
[13]	Ma Xiuzhen, Lu Yan, Zhao Bingbing, Qiu Hongcong, Xu Xun, Wei Min. Effects of total flavonoids from Baeckea frutescens on the migration, invasion and apoptosis of cervical cancer SiHa cells [J]. Journal of International Oncology, 2021, 48(4): 206-211.
[14]	Yu Mingyue, Chen Zhengzheng, Zhao Xuxu, Ren Pingping, Zhang Ying, Ge Li, Zhu Meiling, Zhao Weidong. Factors related to postoperative adjuvant therapy of locally advanced cervical cancer and building of a nomogram prediction model [J]. Journal of International Oncology, 2021, 48(1): 35-40.
[15]	Ding Xuchao, Cao Lili. Common active targeting nano drug delivery systems for cervical cancer [J]. Journal of International Oncology, 2021, 48(1): 61-64.